Shaun Chilton – CEO, Clinigen Group, UK
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Address: 16 John Street, London WC1N 2DL
Tel: +44 (0)20 7421 7400
Web: http://www.specialityeuropeanpharma.com/
Speciality European Pharma was founded in 2006 to acquire, develop, register and commercialise speciality therapeutic products for the expanding European market, with a strong focus on urology.
The company is dedicated to improving the range of products available in Europe to treat urological diseases, including the urological cancers.
Plenaxis® is the company’s lead product. It is a hormonal products to treat advanced and metastatic prostate cancer.
Mitem® is used in the treatment of a range of cancers.
Regurin® is used to treat the symptoms of overactive bladder
Haemopressin® is a critical care product for the treatment of bleeding oesophageal varices.
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
See our Cookie Privacy Policy Here